Procter & Gamble (P&G) has agreed to buy the consumer health business of German drugmaker Merck for €3.4billion (US$4.2 billion), as the US group struggles to ignite sales of its household brands.
The acquisition will give P&G, which owns a wealth of brand names from Pampers diapers to Gillette razors, control of vitamin makers including Seven Seas and Neurobion, which are faster-growing than P&G’s household products.
David Taylor, chief executive of P&G, said the over-the-counter healthcare business would offer “steady, broad-based growth.”
The deal was announced on the same day that the company unveiled another quarter of anemic sales growth and shrinking profit margins as it grapples with discounting from retailers and declining pricing power for its decades-old brands. `
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Turkey Ends Meta Investigation Over Threads and Instagram
Dec 8, 2024 by
CPI
Supreme Court to Hear CCI Petition on Amazon, Flipkart Antitrust Cases
Dec 8, 2024 by
CPI
Senators Urge Antitrust Probe Into FanDuel and DraftKings
Dec 8, 2024 by
CPI
Novo Holdings Secures EU Approval for $16.5 Billion Catalent Acquisition
Dec 8, 2024 by
CPI
US Appeals Court Upholds TikTok Divestment Law, Paving Way for Potential Ban
Dec 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Moats & Entrenchment
Nov 29, 2024 by
CPI
Assessing the Potential for Antitrust Moats and Trenches in the Generative AI Industry
Nov 29, 2024 by
Allison Holt, Sushrut Jain & Ashley Zhou
How SEP Hold-up Can Lead to Entrenchment
Nov 29, 2024 by
Jay Jurata, Elena Kamenir & Christie Boyden
The Role of Moats in Unlocking Economic Growth
Nov 29, 2024 by
CPI
Overcoming Moats and Entrenchment: Disruptive Innovation in Generative AI May Be More Successful than Regulation
Nov 29, 2024 by
Simon Chisholm & Charlie Whitehead